Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
AVTX Avalo Therapeutics
4.000-0.030-0.74%
Close
01/27 16:00 ET
4.0000.0000.00%
Post Mkt Price 01/27 16:00 ET
High
4.160
Open
3.950
Turnover
43.23K
Low
3.900
Pre Close
4.030
Volume
10.76K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Rises By 17.0%
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 40,600 shares, a growth o
PLX, PLBY and THMO Among Mid-day Movers
12 Health Care Stocks Moving In Monday's Intraday Session
GainersJaguar Health (NASDAQ:JAGX) stock rose 6215.8% to $5.35 during Monday's regular session. The current volume of 532.2K shares is 6.8% of Jaguar Health's average full-day volume over the last 100
Avalo Therapeutics Completes Target Enrollment in Phase 2 PEAK Trial
Avalo Announces It Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma
Topline data expected in the second quarter of 2023 WAYNE, Pa. and ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), today announced that it completed enrollment of the 80
Looking Into Avalo Therapeutics's Return On Capital Employed
According to Benzinga Pro, during Q3, Avalo Therapeutics (NASDAQ:AVTX) earned $3.19 million, a 124.58% increase from the preceding quarter. Avalo Therapeutics also posted a total of $14.95 million in
Avalo Therapeutics, Inc. to Post Q4 2022 Earnings of ($0.55) Per Share, Jefferies Financial Group Forecasts (NASDAQ:AVTX)
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) – Equities researchers at Jefferies Financial Group lowered their Q4 2022 EPS estimates for Avalo Therapeutics in a research note issued to inves
Oppenheimer Lowers Avalo Therapeutics (NASDAQ:AVTX) Price Target to $10.00
Avalo Therapeutics (NASDAQ:AVTX – Get Rating) had its price objective decreased by investment analysts at Oppenheimer to $10.00 in a research note issued on Tuesday, Stock Target Advisor reports. Op
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 27.5%
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) saw a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 35,300 shares, a d
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Significant Drop in Short Interest
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 3
Company Overview
More
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
CEO： Dr. Garry A. Neil, M.D.
Market： NASDAQ
Listing Date： 11/13/2015
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet